CGNX Stock Analysis: Cognex | NASDAQ
Scientific & Technical Instruments | NASDAQ, USA | Market Cap: 9.345m USD | 12M Return: 24.4% | US1924221039 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 106M
EPS Trend: 76.7%
Qual. Beats: 4
Rev. Trend: 93.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cognex Corporation is a U.S.-based provider of machine vision hardware and software used to automate manufacturing and distribution processes. Its products capture and analyze visual information to locate, identify, inspect, and measure discrete items in production and logistics environments, such as mobile phones, automotive components, and e-commerce packages. The portfolio includes vision systems (In-Sight), smart cameras, image-based barcode readers (DataMan), vision accessories, and software platforms such as VisionPro, QuickBuild, and the cloud-based OneVision AI platform.
Cognex sells primarily to OEMs and system integrators across the automotive, logistics, packaging, consumer electronics, medical, semiconductor, and consumer products industries. The company operates globally, with a presence in the United States, Europe, and Greater China, and is headquartered in Natick, Massachusetts. It is classified within the Information Technology sector (Electronic Equipment & Instruments sub-industry), and machine vision is a core component of industrial automation, where demand is supported by factory digitization, quality control requirements, and the broader growth of e-commerce fulfillment.
- Apple iPhone production cycles drive consumer electronics machine vision demand
- Greater China revenue declines on weak factory automation investment
- Logistics and e-commerce automation demand recovery boosts DataMan barcode reader sales
| Net Income: 174.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 3.35 > 1.0 |
| NWC/Revenue: 58.21% < 20% (prev 46.83%; Δ 11.38% < -1%) |
| CFO/TA 0.13 > 3% & CFO 276.6m > Net Income 174.8m |
| Net Debt (-331.9m) to EBITDA (279.4m): -1.19 < 3 |
| Current Ratio: 3.93 > 1.5 & < 3 |
| Outstanding Shares: last quarter (170.0m) vs 12m ago 0.85% < -2% |
| Gross Margin: 68.87% > 18% (prev 67.72%; Δ 1.15% > 0.5%) |
| Asset Turnover: 52.07% > 50% (prev 46.40%; Δ 5.68% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.29 (Total Current Assets 849.9m - Total Current Liabilities 216.0m) / Total Assets 2.18b |
| B: 0.18 (Retained Earnings 397.1m / Total Assets 2.18b) |
| C: 0.12 (EBIT TTM 250.4m / Avg Total Assets 2.09b) |
| D: 2.97 (Book Value of Equity 1.63b / Total Liabilities 549.1m) |
| Altman-Z'' = 6.42 = AAA |
| DSRI: 1.05 (Receivables 228.9m/186.1m, Revenue 1.09b/929.6m) |
| GMI: 0.98 (GM 67.72% / 68.87%) |
| AQI: 0.95 (AQ_t 0.57 / AQ_t-1 0.60) |
| SGI: 1.17 (Revenue 1.09b / 929.6m) |
| TATA: -0.05 (NI 174.8m - CFO 276.6m) / TA 2.18b) |
| Beneish M = -2.91 (Cap -4..+1) = A |
As of October 29, 2026, the stock is trading at USD 58.43 with a total of 1,375,194 shares traded. Over the past week, the price has changed by +0.65%, over one month by -0.54%, over three months by -3.06% and over the past year by +24.36%.
Current recommended Stop Loss: 55.30 (which is 5.4% or 1.2 ATR below the current price).
Cognex has received a consensus analysts rating of 4.15. Therefore, it is recommended to buy CGNX.
- StrongBuy: 9
- Buy: 5
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 79.4 | 35.8% |
P/E Trailing = 56.6837
P/E Forward = 29.4985
P/S = 8.5817
P/B = 6.0856
P/EG = 2.7121
Revenue TTM = 1.09b USD
EBIT TTM = 250.4m USD
EBITDA TTM = 279.4m USD
Long Term Debt = 60.2m USD (estimated: total debt 72.5m - short term 12.3m)
Short Term Debt = 12.3m USD (from shortTermDebt, last quarter)
Debt = 72.5m USD (from shortLongTermDebtTotal, last quarter) (leases 72.5m already included)
Net Debt = -331.9m USD (calculated: Debt 72.5m - CCE 404.4m)
Enterprise Value = 9.01b USD (9.34b + Debt 72.5m - CCE 404.4m)
Interest Coverage Ratio = unknown (Ebit TTM 250.4m / Interest Expense TTM 0.0)
EV/FCF = 33.59x (Enterprise Value 9.01b / FCF TTM 268.3m)
FCF Yield = 2.98% (FCF TTM 268.3m / Enterprise Value 9.01b)
FCF Margin = 24.64% (FCF TTM 268.3m / Revenue TTM 1.09b)
Net Margin = 16.05% (Net Income TTM 174.8m / Revenue TTM 1.09b)
Gross Margin = 68.87% ((Revenue TTM 1.09b - Cost of Revenue TTM 339.0m) / Revenue TTM)
Gross Margin QoQ = 70.65% (prev 71.13%)
Tobins Q-Ratio = 4.14 (Enterprise Value 9.01b / Total Assets 2.18b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 72.5m)
Taxrate = 32.25% (83.2m / 258.0m)
NOPAT = 169.7m (EBIT 250.4m * (1 - 32.25%))
Current Ratio = 3.93 (Total Current Assets 849.9m / Total Current Liabilities 216.0m)
Debt / Equity = 0.04 (Debt 72.5m / totalStockholderEquity, last quarter 1.63b)
Debt / EBITDA = -1.19 (Net Debt -331.9m / EBITDA 279.4m)
Debt / FCF = -1.24 (Net Debt -331.9m / FCF TTM 268.3m)
Total Stockholder Equity = 1.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.36% (Net Income 174.8m / Total Assets 2.18b)
RoE = 11.48% (Net Income TTM 174.8m / Total Stockholder Equity 1.52b)
RoCE = 15.82% (EBIT 250.4m / Capital Employed (Equity 1.52b + L.T.Debt 60.2m))
RoIC = 8.83% (NOPAT 169.7m / Invested Capital 1.92b)
WACC = 12.39% (E(9.34b)/V(9.42b) * Re(12.49%) + D(72.5m)/V(9.42b) * Rd(0.0%) * (1-Tc(0.32)))
Discount Rate = 12.49% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -83.85 | Cagr: -0.67%
[DCF] Terminal Value 66.04% ; FCFF base≈232.8m ; Y1≈266.9m ; Y5≈392.8m
[DCF] Fair Price = 22.40 (EV 3.44b - Net Debt -331.9m = Equity 3.77b / Shares 168.2m; r=12.39% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 76.66 | EPS CAGR: 23.35% | SUE: 1.15 | # QB: 4
Revenue Correlation: 93.40 | Revenue CAGR: 9.27% | SUE: -0.15 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.52 | Chg30d=+0.60% | Revisions=+25% | Analysts=17
EPS current Year (2026-12-31): EPS=1.69 | Chg30d=+0.12% | Revisions=+0% | GrowthEPS=+66.2% | GrowthRev=+15.3%
EPS next Year (2027-12-31): EPS=2.02 | Chg30d=-0.12% | Revisions=+17% | GrowthEPS=+19.3% | GrowthRev=+11.0%
[Analyst] Revisions Ratio: +18% (up=5, down=3)